Activity of S-1 in advanced or recurrent gastric cancer patients after failure of prior chemotherapy, including irinotecan + cisplatin or fluorouracil (Except S-1)

Japanese Journal of Clinical Oncology

Volumn 39, Issue 5, 2009, Pages 332-335

  Ono, Akira ^a   Boku, Narikazu ^a   Onozawa, Yusuke ^a   Hironaka, Shuichi ^a   Fukutomi, Akira ^a   Yasui, Hiroshi ^a   Yamazaki, Kentaro ^a   Yoshino, Takayuki ^a   Taku, Keisei ^a   Kojima, Takashi ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

Gastric cancer; S 1; Second line

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; DOCETAXEL; FLUOROURACIL; IRINOTECAN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HOT FLUSH; HUMAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MALE; MONOTHERAPY; NAUSEA; NEUTROPENIA; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; RETROSPECTIVE STUDY; REVIEW; STOMACH CANCER; SURVIVAL RATE; SURVIVAL TIME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OXONIC ACID; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TEGAFUR;

EID: 65549148495     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp018     Document Type: Review

References (11)

1. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer (JCOG9205). J Clin Oncol 2003;21:54-9
2. Narahara H, Koizumi W, Hara T, Takagane A, Akiya T, Takagi M, et al. Randomized phase III study of S-1 alone versus S-1 + cisplatin in the treatment of advanced gastric cancer (The SPIRITS trial). Lancet Oncol 2008;9:215-21.
3. Hironaka S, Zenda S, Boku N, Fukutomi A, Yoshino T, Onozawa Y. Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer 2006;9:14-8.
4. Kodera Y, Ito S, Mochizuki Y, Fujitake S, Koshikawa K, Kanayama Y, et al. A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 study). Anticancer Res 2007;27:2667-72.
5. Ajani JA, Baker J, Pisters PW, Ho L, Mansfield PF, Feig BW, et al. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma. Oncology (Williston Park, NY) 2002;16:16-8.
6. Ueda S, Hironaka S, Boku N, Fukutomi A, Yoshino T, Onozawa Y. Combination chemotherapy with irinotecan and cisplatin in pretreated patients with unresectable or recurrent gastric cancer. Gastric Cancer 2006;9:203-7.
7. Giuliani F, Molica S, Maiello E, Battaglia C, Gebbia V, Di Bisceglie M, et al. Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer; a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106). Am J Clin Oncol 2005;28:581-5.
8. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its anticancer activity in rats. Cancer Res 1993;53:4004-9.
9. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For S-1 cooperative gastric cancer study group. Oncology 2000;58:191-7.
10. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Tagichi T. Late phase II study of novel fluoropyrimidine anti cancer drug S-1 in advanced gastric cancer patients. Eur J Cancer 2005;34:1715-20.
11. Japanese society of gastric cancer. Treatment of Gastric Cancer Guideline. 2nd ed. Tokyo: Kanehara-shuppan; 2004.